Abstract 381P
Background
Oral squamous cell carcinoma (OSCC) is highly prevalent in South-East Asia including Indonesia. Recurrence and early mortality in OSCC patients cause significant health burden. Subclassification of patients with high risks of locoregional recurrence and early death is beneficial for planning of treatment intensification and surveillance.
Methods
Formalin-fixed paraffin embedded (FFPE) tissues of OSCC were immuno-stained and analyzed for p16 expression. Semi-quantitative German scoring system for p16 was used. Risk factors and clinical parameters of OSCC patients were collected and compared to identify factors associated with recurrences and overall survival.
Results
OSCC recurrences and mortality were observed in in 82% and 78% patients (N=60) after a median follow-up of 32 months. Larger tumor size (T3 and T4) was significantly associated with both recurrences and mortality (OR = 3.967,95% CI = 1.007-15.618 and OR = 5.885, 95% CI = 1.541-22.47, respectively). Positive p16 staining was observed in 31% of tumors. Patients with p16 -positive expression were significantly associated with longer recurrence-free and overall survivals (medians of recurrence-free survivals were 31.2 vs 19.0 months, P=0.038 and overall survivals were 39.0 vs 28.8 months, P=0.048; respectively). Other clinical variables including early stages, negative cervical nodes, non-keratinizing tumors, and negative surgical margin status were significantly associated with longer recurrence-free and survivals (log-rank tests, P<0.05).
Conclusions
P16 -positive staining, early stages, positive cervical lymph node infiltration, and positive surgical margins are associated with better prognosis in OSCC patients. The study emphasizes the importance of early detection and the potential use of p16 and other clinical markers as prognostic markers in OSCC patients.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
S. L. Anwar.
Funding
Universitas Gadjah Mada.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
62P - Combination of chemotherapy with endocrinal therapy as upfront treatment of metastatic breast cancer in hormone receptor- positive, HER2 -negative disease: A phase II randomised clinical trial
Presenter: Mariam Saleh
Session: Poster Display
Resources:
Abstract
63P - Efficacy and safety of eribulin plus carboplatin combination for HER2-negative metastatic breast cancer
Presenter: Mengqian Ni
Session: Poster Display
Resources:
Abstract
64P - Unmet needs following metastatic breast cancer in a middle-income Asian country
Presenter: Nirmala Bhoo-Pathy
Session: Poster Display
Resources:
Abstract
66P - Utidelone-based therapy in metastatic solid tumors after failure of standard therapies: A prospective, multicenter, single-arm trial
Presenter: Jianjun Zhang
Session: Poster Display
Resources:
Abstract
67P - Efficacy and safety of trastuzumab biosimilar in HER2+ve metastatic breast cancer: A multicenter phase III study
Presenter: krishna Mohan
Session: Poster Display
Resources:
Abstract
68P - Neratinib in combination with fulvestrant and or palbociclib can overcome endocrine resistance in HER2-low/ ER+ breast cancer
Presenter: Maryam Arshad
Session: Poster Display
Resources:
Abstract
69P - A multicenter, retrospective, real-world study of inetetamab combined with pyrotinib and vinorelbine as treatment for HER2-positive metastatic breast cancer
Presenter: Nan Jin
Session: Poster Display
Resources:
Abstract
70P - Overall survival of eribulin, trastuzumab, and pertuzumab as first-line therapy for patients with HER2-positive metastatic breast cancer: A phase II, single-arm clinical trial
Presenter: Kenichi Inoue
Session: Poster Display
Resources:
Abstract
71P - Efficacy and safety of disitamab vedotin after trastuzumab for HER2 -positive breast cancer: A real-world data of retrospective study
Presenter: Chao Li
Session: Poster Display
Resources:
Abstract
72P - Real-world data on the efficacy of T-DM1 biosimilar for the treatment of HER2-positive metastatic breast cancer patients: Outcomes from a single center retrospective study in India
Presenter: Kaushal Patel
Session: Poster Display
Resources:
Abstract